These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24277152)

  • 1. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission.
    Malbec M; Porrot F; Rua R; Horwitz J; Klein F; Halper-Stromberg A; Scheid JF; Eden C; Mouquet H; Nussenzweig MC; Schwartz O
    J Exp Med; 2013 Dec; 210(13):2813-21. PubMed ID: 24277152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
    Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV transmission from infected CD4+ T cells to allogenic T and dendritic cells is inhibited by broadly neutralizing antibodies.
    Ducloy C; Su B; Mayr L; Klingler J; Decoville T; Schmidt S; Laumond G; Salomé N; Bahram S; Moog C
    AIDS; 2018 Jun; 32(10):1239-1245. PubMed ID: 29683853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bystander CD4 T-cell death is inhibited by broadly neutralizing anti-HIV antibodies only at levels blocking cell-to-cell viral transmission.
    Luo X; Mouquet H; Schwartz O; Greene WC
    J Biol Chem; 2021 Oct; 297(4):101098. PubMed ID: 34418431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells.
    Dufloo J; Planchais C; Frémont S; Lorin V; Guivel-Benhassine F; Stefic K; Casartelli N; Echard A; Roingeard P; Mouquet H; Schwartz O; Bruel T
    Nat Commun; 2022 Feb; 13(1):630. PubMed ID: 35110562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection.
    Su B; Peressin M; Ducloy C; Penichon J; Mayr LM; Laumond G; Schmidt S; Decoville T; Moog C
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1187-91. PubMed ID: 26252799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadly neutralizing antibodies potently inhibit cell-to-cell transmission of semen leukocyte-derived SHIV162P3.
    Suphaphiphat K; Tolazzi M; Hua S; Desjardins D; Lorin V; Dereuddre-Bosquet N; Mouquet H; Scarlatti G; Grand RL; Cavarelli M
    EBioMedicine; 2020 Jul; 57():102842. PubMed ID: 32619962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 cell-to-cell transmission and broadly neutralizing antibodies.
    Dufloo J; Bruel T; Schwartz O
    Retrovirology; 2018 Jul; 15(1):51. PubMed ID: 30055632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of Neutralized HIV-1 by Dendritic Cells Is Dependent on the Epitope Bound by the Antibody.
    van Montfort T; Thomas AA; Krawczyk PM; Berkhout B; Sanders RW; Paxton WA
    J Immunol; 2015 Oct; 195(8):3759-68. PubMed ID: 26355155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.
    Reh L; Magnus C; Schanz M; Weber J; Uhr T; Rusert P; Trkola A
    PLoS Pathog; 2015 Jul; 11(7):e1004966. PubMed ID: 26158270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection.
    Sagar M; Akiyama H; Etemad B; Ramirez N; Freitas I; Gummuluru S
    J Infect Dis; 2012 Apr; 205(8):1248-57. PubMed ID: 22396600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. eCD4-Ig Variants That More Potently Neutralize HIV-1.
    Fetzer I; Gardner MR; Davis-Gardner ME; Prasad NR; Alfant B; Weber JA; Farzan M
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
    McGuire AT; Glenn JA; Lippy A; Stamatatos L
    J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
    Zhang Y; Chapman JH; Ulcay A; Sutton RE
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.
    Morgand M; Bouvin-Pley M; Plantier JC; Moreau A; Alessandri E; Simon F; Pace CS; Pancera M; Ho DD; Poignard P; Bjorkman PJ; Mouquet H; Nussenzweig MC; Kwong PD; Baty D; Chames P; Braibant M; Barin F
    J Acquir Immune Defic Syndr; 2016 Mar; 71(3):237-45. PubMed ID: 26413851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity.
    Sánchez-Palomino S; Massanella M; Carrillo J; García A; García F; González N; Merino A; Alcamí J; Bofill M; Yuste E; Gatell JM; Clotet B; Blanco J
    Vaccine; 2011 Jul; 29(32):5250-9. PubMed ID: 21609746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.